DENVER–(BUSINESS WIRE)–Lumen Technologies, Inc. (“Lumen,” “us,” “we,” or “our”) (NYSE: LUMN) today announced that its Board of Directors has approved the voluntary transfer of the listing of Lumen’s common stock, as well as the 6.500% Notes due 2051 (CTGG) and 6.750% Notes due 2052 (CTHH) issued by its wholly owned subsidiary, Qwest Corporation (the “Securities”), from the New York Stock Exchange (“NYSE”) to The Nasdaq Stock Market LLC (“Nasdaq”). Lumen and Qwest Corporation have filed applic
Month: September 2026
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystrophy at the 31st Annual Congress of the World Muscle Society (WMS), taking place Sept. 29 – Oct. 3, in Hiroshima, Japan. Data at WMS includes a late-breaking poster presentation on delandistrogene moxeparvovec efficacy and safety in older, ambulatory Duchenne patients in Sarepta’
OLDWICK, N.J.–(BUSINESS WIRE)–AM Best will sponsor and exhibit at the Association of Insurance Compliance Professionals (AICP) Annual Conference at the Louisville Marriott Downtown in Kentucky, Oct. 10–13, 2026. Join Director of Product Strategy Scott Jordan and Managers John Czuba and Matt Radman to learn more about the resources AM Best offers to insurance professionals, including:Best’s State Rate Filings®: Keep up with U.S. property/casualty and life/health program innovations, find out wh
COLUMBUS, Ohio–(BUSINESS WIRE)–McGraw Hill, Inc. (the “Company”) announced today that McGraw-Hill Education, Inc., the Company’s wholly-owned subsidiary (the “Issuer”) intends, subject to market conditions, to offer $500 million in aggregate principal amount of senior secured notes due 2033 (the “Notes”) in a private offering (the “Offering”). The Notes will be guaranteed by the Issuer’s parent, Mav Intermediate Holding II Corporation, and certain of the Issuer’s direct and indirect subsidiar
LONDON–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be
LONDON–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be
LONDON–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be
LONDON–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be
AUSTIN, Texas, Sept. 25, 2026 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the fiscal year ended June 30, 2026.
Financial Highlights & Fiscal Year Developments
- As of June 30, 2026, the Company had deployed the TRACER 1000 in approximately 37 locations in 16 countries across the United States, Europe and Asia.
- The Company launched its Labrador ruggedized Handheld Gas Chromatograph designed to bring laboratory-grade volatile organic compound analysis directly to the point of investigation.
- The Board of Directors of the Company approved a strategic initiative focused on potential future lunar resource development, autonomous lunar industrial infrastructure, Moon based advanced computing, semiconductor, manufacturing, lunar power generation and power infrastructure, mining, chemical manufacturing, product transportation and equipment leasing opportunities on the Moon through its newly formed subsidiary, Lunar Power and Light Corporation. As part of the initiative, Astrotech intends to evaluate and potentially develop infrastructure technologies that could support semiconductor processing, advanced computing systems, and quantum computing manufacturing operations on the lunar surface.
- Total operating expenses were $14 million, a decline of 6% during the fiscal year ended June 30, 2026, compared to the fiscal year ended June 30, 2025.
- Astrotech’s consolidated balance sheet consisted of $11.3 million in cash and cash equivalents and short-term investments as of June 30, 2026, which the Company believes will support operating expenses and capital expenditure requirements.
“Our fiscal year 2026 results reflect an important period of investment and progress. We have advanced several priorities that strengthen the foundation for scalable growth, including the launch of our new lunar resource and infrastructure strategic initiatives. We believe these initiatives could expand our addressable opportunities and position us to better serve customers over the long term. We enter the new year focused on executing on these opportunities with the goal of converting pipeline opportunities into revenue growth,” stated Thomas B. Pickens, III, Astrotech’s Chairman, Chief Executive Officer and Chief Technology Officer.
About Astrotech Corporation
Astrotech (Nasdaq: ASTC) is a mass spectrometry company that creates, operates, and scales innovative businesses through its wholly owned subsidiaries. Each subsidiary leverages Astrotech’s core technology to serve specialized markets:
- 1st Detect develops, manufactures, and markets trace detection systems for security and narcotics screening applications.
- AgLAB designs process analyzers tailored to the agriculture industry.
- Pro-Control produces solutions for in-situ chemical process control in industrial manufacturing.
- EN-SCAN, Inc. delivers portable, ruggedized environmental testing solutions that integrate gas chromatography and mass spectrometry for use in challenging field environments.
- Lunar Power and Light focused on potentially developing infrastructure technologies that could support semiconductor processing, advanced computing systems, and quantum computing manufacturing operations on the lunar surface.
Astrotech is headquartered in Austin, Texas. For more information, visit www.astrotechcorp.com
Forward-Looking Statements
This press release contains “forward-looking statements” that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, but are not limited to, the adverse impact of inflationary pressures, including significant increases in fuel costs, global economic conditions and events related to these conditions, including the ongoing wars in Ukraine and the middle east, the Company’s use of proceeds from the common stock offerings, whether we can successfully complete the development of our new products and proprietary technologies, whether we can obtain the FDA and other regulatory approvals required to market our products under development in the United States or abroad, whether the market will accept our products and services and whether we are successful in identifying, completing and integrating acquisitions, the Company’s lunar infrastructure initiatives, potential NASA selection, funding, awards or contracts, technology development, partnerships, autonomous systems, lunar resource mining and processing, advanced manufacturing, power development, artificial intelligence, quantum computing, advanced semiconductor materials and commercial lunar activity, future engineering and testing, technology qualification, commercialization and potential lunar resource deployment and long-duration energy storage; and the Company’s ability to finance, validate, launch, operate or commercialize related systems, and the potential effects of the addition of advisors, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
Any forward-looking statements in this document should be evaluated in light of these important risk factors. The contemplated lunar energy-storage application remains in the evaluation and development stage. While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others mentioned herein. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Moreover, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. In addition, any forward- looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to correct or update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Company Contact:
Scott Bartley
Interim Chief Financial Officer, Astrotech Corporation
(512) 485-9530
Tables follow
| ASTROTECH CORPORATION Consolidated Statements of Operations and Other Comprehensive Loss (In thousands, except per share data) |
||||||||
| June 30, | ||||||||
| 2026 | 2025 | |||||||
| Revenue | $ | 913 | $ | 1,049 | ||||
| Cost of revenue | 696 | 574 | ||||||
| Gross profit | 217 | 475 | ||||||
| Operating expenses: | ||||||||
| Selling, general and administrative | 7,871 | 7,067 | ||||||
| Research and development | 6,484 | 8,142 | ||||||
| Total operating expenses | 14,355 | 15,209 | ||||||
| Loss from operations | (14,138 | ) | (14,734 | ) | ||||
| Interest and dividend income | 471 | 1094 | ||||||
| Realized loss | (543 | ) | (5 | ) | ||||
| Other income and expense, net | (213 | ) | (203 | ) | ||||
| Total other income(expense) | (285 | ) | 886 | |||||
| Loss from operations before income taxes | (14,423 | ) | (13,848 | ) | ||||
| Income tax benefit /(expense) | (4 | ) | (2 | ) | ||||
| Net loss | $ | (14,427 | ) | $ | (13,850 | ) | ||
| Weighted average common shares outstanding: | ||||||||
| Basic and diluted | 1,700 | 1,665 | ||||||
| Basic and diluted net loss per common share: | ||||||||
| Net loss per common share | $ | (8.49 | ) | $ | (8.32 | ) | ||
| Other comprehensive loss, net of tax: | ||||||||
| Net loss | $ | (14,427 | ) | $ | (13,850 | ) | ||
| Available-for-sale securities: | ||||||||
| Net unrealized gain | 548 | 313 | ||||||
| Total comprehensive loss | $ | (13,879 | ) | $ | (13,537 | ) | ||
| ASTROTECH CORPORATION Consolidated Balance Sheets (In thousands, except share and per share data) |
||||||||
| June 30, | ||||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 8,387 | $ | 3,100 | ||||
| Short-term investments | 2,947 | 15,108 | ||||||
| Accounts receivable | 124 | 485 | ||||||
| Inventory, net: | ||||||||
| Raw materials | 2,926 | 2,194 | ||||||
| Work-in-process | 9 | 425 | ||||||
| Finished goods | 1,179 | 310 | ||||||
| Prepaid expenses and other current assets | 354 | 353 | ||||||
| Total current assets | 15,926 | 21,975 | ||||||
| Property and equipment, net | 2,383 | 2,395 | ||||||
| Intangible assets, net | 50 | 48 | ||||||
| Operating lease right-of-use assets, net | 1,834 | 2,225 | ||||||
| Other assets, net | 314 | 346 | ||||||
| Total assets | $ | 20,507 | $ | 26,989 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 581 | $ | 1,066 | ||||
| Payroll related accruals | 482 | 529 | ||||||
| Accrued expenses and other liabilities | 912 | 451 | ||||||
| Lease liabilities, current | 282 | 405 | ||||||
| Total current liabilities | 2,257 | 2,451 | ||||||
| Accrued expenses and other liabilities, net of current portion | 54 | 164 | ||||||
| Lease liabilities, net of current portion | 2,024 | 2,274 | ||||||
| Total liabilities | 4,335 | 4,889 | ||||||
| Commitments and contingencies (Note 14) | ||||||||
| Stockholders’ equity | ||||||||
| Convertible preferred stock, $0.001 par value, 2,500,000 shares authorized; 280,898 shares of Series D issued and outstanding at June 30, 2026 and 2025, respectively | — | — | ||||||
| Common stock, $0.001 par value, 250,000,000 shares authorized at June 30, 2026 and 2025 respectively; 2,009,050 and 1,769,269 shares issued at June 30, 2026 and 2025 respectively; 1,998,734 and 1,758,953 outstanding at June 30, 2026 and 2025, respectively | 190,643 | 190,643 | ||||||
| Treasury shares, 10,316 shares at June 30, 2026 and 2025, respectively | (119 | ) | (119 | ) | ||||
| Additional paid-in capital | 91,261 | 83,310 | ||||||
| Accumulated deficit | (265,297 | ) | (250,870 | ) | ||||
| Accumulated other comprehensive loss | (316 | ) | (864 | ) | ||||
| Total stockholders’ equity | 16,172 | 22,100 | ||||||
| Total liabilities and stockholders’ equity | $ | 20,507 | $ | 26,989 | ||||
Originally published on CVS Health Company Newsroom
The demand for reliable energy continues to grow, and for CVS Health, dependable operations are essential to serving millions of patients and customers across the country. That’s why we’re expanding our use of renewable electricity and investing in energy solutions that help reduce emissions, strengthen business resilience and support uninterrupted care. These efforts are part of our goal to source 50% of our energy from renewable electricity by 2040 while building a healthier, more sustainable future for the communities we serve.
Through new and expanded power purchase agreements (PPAs), we’re increasing our use of clean electricity to support our operations. These efforts are part of our broader approach to sustainability, one that’s rooted in improving health outcomes over time.
“As a health solutions company, we recognize that the health of our communities is closely connected to the health of our environment,” said Jenny McColloch, Chief Sustainability Officer of CVS Health. “By investing in renewable energy, we’re reducing emissions, strengthening the resilience of our operations and ensuring continuity of care for the patients and customers we serve in communities across the country.”
Why renewable energy agreements matter
The need for reliable, affordable energy is growing, especially as industries expand and power demand increases. Across sectors, organizations are turning to renewable energy sources to strengthen long-term energy stability and manage costs.
For CVS Health, renewable energy agreements help support the stores, pharmacies, clinics and facilities that patients and customers rely on every day. They also help strengthen the energy system and support a cleaner future for the communities we serve.
What’s happening
Since 2022, we’ve made seven large-scale investments in renewable energy. Most recently in Maryland and putting energy-saving solutions into practice across our operations to reduce energy use and improve efficiency.
So far, we’ve secured agreements to source more than 969,000 megawatt hours (MWh) of clean energy as these projects come online. These efforts are helping move us closer to our goal of sourcing 50% renewable electricity by 2040. In 2025, renewable electricity represented approximately 33% of our total electricity use.
How a renewable energy power purchase agreement works
A power purchase agreement is a long-term contract that supports the development of renewable energy projects, such as solar and wind farms, while allowing CVS Health to purchase renewable electricity without building or operating the projects ourselves.
Here’s how it works in practice:
- Renewable energy is generated offsite from projects across the U.S.
- That energy is delivered to the grid and helps increase the overall supply of clean electricity
- CVS Health receives the environmental benefits, which are credited against our electricity use
These agreements typically span multiple years, providing predictable access to clean energy sources while supporting the development of new renewable capacity.
What clean energy means for CVS Health’s carbon footprint
Our renewable energy investments are a key part of reducing our Scope 2 GHG emissions – the emissions associated with the electricity we use to operate our stores, clinics and facilities.
By increasing the amount of clean electricity in our energy mix, we’re making steady progress toward lowering our overall carbon footprint.
These efforts help us:
- Improve the efficiency of how we operate
- Support long-term energy reliability
- Contribute to a more sustainable energy system
All of which ultimately support the communities and patients we serve. They also help improve air quality by reducing reliance on fossil fuels, which can contribute to respiratory and cardiovascular health issues. At the same time, investing in a more resilient energy system helps us continue serving patients and communities during periods of increased demand and extreme weather.
The bottom line
Investing in renewable energy is one way we’re helping build a healthier future. By reducing emissions, supporting cleaner air and strengthening the resilience of our operations, we’re helping ensure we can continue caring for patients and serving communities today and in the years ahead.